Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Cretostimogene grenadenorepvec by CG Oncology for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer): Likelihood of Approval
Cretostimogene grenadenorepvec is under clinical development by CG Oncology and currently in Phase III for Non Muscle Invasive Bladder Cancer...
Data Insights
Risk adjusted net present value: What is the current valuation of CG Oncology's Cretostimogene grenadenorepvec?
Cretostimogene grenadenorepvec is an oncolytic virus commercialized by CG Oncology, with a leading Phase III program in Non Muscle Invasive...